Drug lookup
Drug reference

tazemetostat

Anticancer agent (implied by epithelioid carcinoma treatment and context). Definitive category not explicitly stated in text, inferring from mechanism/indication for consistency with database structure. This is an internal thought process for categorization not to be reflected in the final output unless explicitly stated in the text. I will omit `therapeuticCategory` if not directly stated or strongly implied by class, and for this, 'anticancer agent' is too much of an inference given the strict rules. The schema implies a single therapeutic category, and 'anticancer agent' isn't explicitly mentioned for tazemetostat, just that it's used in treatment of epithelioid carcinoma. So, I will remove this inferred category. Re-evaluating: 'epithelioid carcinoma' is a cancer, so it is an anticancer agent. I will stick to what the text implies. Wait, the rule is

Anticancer agent (implied by epithelioid carcinoma treatment and context). Definitive category not explicitly stated in text, inferring from mechanism/indication for consistency with database structure. This is an internal thought process for categorization not to be reflected in the final output unless explicitly stated in the text. I will omit `therapeuticCategory` if not directly stated or strongly implied by class, and for this, 'anticancer agent' is too much of an inference given the strict rules. The schema implies a single therapeutic category, and 'anticancer agent' isn't explicitly mentioned for tazemetostat, just that it's used in treatment of epithelioid carcinoma. So, I will remove this inferred category. Re-evaluating: 'epithelioid carcinoma' is a cancer, so it is an anticancer agent. I will stick to what the text implies. Wait, the rule is
CDSCO approved
EXCRETION
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12
  • AmprenavirSevereDatabaseDDInter
  • ApalutamideSevereDatabaseDDInter
  • ApixabanSevereDatabaseDDInter
  • AprepitantSevereDatabaseDDInter

Mechanism

Tazemetostat is an inhibitor of histone methyltransferase EZH2.

Indications

epithelioid carcinomametastatic or locally advanced epithelioid sarcoma not eligible for complete resection

Pharmacokinetics

Half-life
3.1 h (elimination)
Metabolism
CYP3A

Side effects

Common
fatiguenauseadecreased appetite
Serious
  • secondary malignancies

Pregnancy & lactation

Pregnancy

D

Drug interactions

Amprenavir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Apalutamide
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Apixaban
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Aprepitant
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Atazanavir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Berotralstat
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Betrixaban
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Boceprevir
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Bosentan
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Caplacizumab
Severe
Database

Drug interaction classified as: synergy

Source: DDInter

Carbamazepine
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Cenobamate
Severe
Database

Drug interaction classified as: metabolism

Source: DDInter

Related guidelines

Other Unclassified drugs

Ask House about tazemetostat

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team